2004 4Q and Full-Year Guidance
- Net interest expense in 4Q of approximately
- Tax rate of approximately 30%
- Amortization for 2004 estimated at $13.2M
- Compensation charges from stock options of $2.3M
- Write-off of deferred financing of $0.5M
- Proteomics closure of $3.1M
- Reduction in force of $0.6M